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Introduction

Dolutegravir reduces migration of HTR-8 cells

Results

Introduction
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Dolutegravir inhibited MMPs activities in HTR-8 cells in both normoxic and hypoxic conditions
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Dolutegravir (DTG) is recommended as both, part of first-line and of either switching or salvage regimens for the
treatment of HIV-1 infection in both resource-rich countries and resource-limited countries (RRCs and RLCs).

**
*

ns

F

W o u n d C lo s u re (% )

100

Due to a breakthrough pricing agreement made in September 2017 to accelerate the availability of generic DTGbased regimen in RLCs at the cost of $75 US dollars/person/year, approximately 100 RLCs have implemented
a transition to DTG-based regimens in national treatment guidelines by mid-2020.
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It is estimated that in 5 years, 15 million HIV-1 infected people will be treated with DTG in RLCs. This includes
women of child-bearing age, a significant infected population. Currently, there are 15.5 million women, 15-49 years
old, living with HIV worldwide.
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Dolutegravir reduces invasion function of HTR-8 cells

Due to current inclusion of DTG-based regimen in national guidelines for treatment of pregnant women or those of
child-bearing potential worldwide, and rising pretreatment resistance in women to non-nucleoside reverse
transcriptase inhibitors (NNRTIs) in RLCs, majority of HIV-1 infected women are and will be treated with DTGbased regimen.

However, recent concerns emerged for usage of DTG in pregnant women or those of child-bearing age. Notably,
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Dolutegravir decreased HIF-1α expression in HTR-8 cells
under both normoxic and hypoxic conditions
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DTG-based antiretroviral regimen (ART) have been linked to birth defects seen as a consequence of
periconceptional usages.
Given the large number of fetuses exposed to DTG in utero, it is important to assure their safety from drug
exposures during their development. Thus, identifying unknown developmental adverse events and underlying
mechanisms for DTG-associated adverse fetal development outcomes has gained clinical and basic research
interest.

To this end, we showed that DTG binds to Zn++ at the catalytic domain and inhibits activity of matrix
metalloproteinases (MMPs).
It is known that activity of MMP-2 and MMP-9 are required for the successful invasion of trophoblasts during early
pregnancy. Abnormalities in the activities of these proteins can influence impairment in placental implantation,
vascular restructuring, and fetal development.
There is a research gap of known adverse events reflecting DTG-associated trophoblasts impairments.

Conclusion
➢ DTG inhibits activity of MMP-2 under normoxic condition and of both MMP-2 and -9 under hypoxic conditions in
HTR-8 trophoblastic cells
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➢ DTG decreases HIF-1α expression under both normoxic and hypoxic conditions.

Beclin 1

Herein, we determine effects of DTG exposure on migration and invasion abilities of trophoblastic cells (HTR-8
cells) and identify underlying mechanisms.

➢ DTG decreases Beclin-1 expression, potentially inhibiting autophagy.
➢ DTG reduces migration and invasion abilities of HTR-8 trophoblastic cells.

Hypothesis
We hypothesize that DTG inhibition of MMPs activities reduces invasion abilities of trophoblasts.

➢ DTG-induced decrease in HIF-1α expression observed in mice placenta following DTG administration at human
relevant therapeutic dosage.

Methods

➢ Overall, our preliminary work concludes that DTG can potentially affect placental development by affecting HIF-1α
expression and MMPs activities.

In vitro

In vivo

Dolutegravir decreased HIF-1α expression in placenta at human therapeutic dosage
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